WO2001017546A1 - Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions - Google Patents
Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions Download PDFInfo
- Publication number
- WO2001017546A1 WO2001017546A1 PCT/US2000/024505 US0024505W WO0117546A1 WO 2001017546 A1 WO2001017546 A1 WO 2001017546A1 US 0024505 W US0024505 W US 0024505W WO 0117546 A1 WO0117546 A1 WO 0117546A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- less
- composition
- cyclosporine
- nanoparticulate
- surface stabilizer
- Prior art date
Links
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/145—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K38/00—Medicinal preparations containing peptides
- A61K38/04—Peptides having up to 20 amino acids in a fully defined sequence; Derivatives thereof
- A61K38/12—Cyclic peptides, e.g. bacitracins; Polymyxins; Gramicidins S, C; Tyrocidins A, B or C
- A61K38/13—Cyclosporins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K9/00—Medicinal preparations characterised by special physical form
- A61K9/14—Particulate form, e.g. powders, Processes for size reducing of pure drugs or the resulting products, Pure drug nanoparticles
- A61K9/141—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers
- A61K9/146—Intimate drug-carrier mixtures characterised by the carrier, e.g. ordered mixtures, adsorbates, solid solutions, eutectica, co-dried, co-solubilised, co-kneaded, co-milled, co-ground products, co-precipitates, co-evaporates, co-extrudates, co-melts; Drug nanoparticles with adsorbed surface modifiers with organic macromolecular compounds
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P31/00—Antiinfectives, i.e. antibiotics, antiseptics, chemotherapeutics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P33/00—Antiparasitic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
Definitions
- the present invention is directed to nanoparticulate compositions comprising amorphous cyclosporine, or a mixture of amorphous and crystalline cyclosponne. and methods of making and using such compositions.
- Cyclosporine is a hydrophobic, cyclic, undecapeptide that exerts immunosuppressive, antiinflammatory, antifungal, and antiparasitic activities. Immunosuppressive medications play a large part of the management of many pediatric illnesses. Cyclosporine is the primary tool used to prevent rejection following solid organ and bone marrow transplantation; the drug helped revolutionize transplantation by improving transplant survival, reducing hospitalization, and reducing patient morbidity. It has been estimated that cyclosporine is given to more than 90% of children who have received a kidney transplant in the United States.
- Cyclosporine also has been effective in various other autoimmune conditions such as uveitis, psoriasis, type I diabetes mellitus, rheumatoid arthritis, inflammatory bowel disease, certain nephropathies, refractory
- Cyclosporine is in clinical use worldwide under the trade names SANDIMMUNE ® (Novartis), NEORAL ® (Novartis), and SANGCYA ® (SangStat).
- SANDIMMUNE ® introduced in 1983, suffered from poor and widely variable absorption rates. This prompted development of a second generation cyclosporine formulation, NEORAL ® , which is a microemulsion formulation having better absorption than SANDIMMUNE ® - both in quantity and consistency. Since 1995, when NEORAL ® was introduced, about 70% of patients have switched from SANDIMMUNE ® to NEORAL ® . indicating the severity of poor and inconsistent absorption of cyclosporine.
- SANGCYA ® which is a modified oral solution bioequivalent to NEORAL ® , was introduced in 1998. Cyclosporine is administered orally and intravenously (IV). After oral administration, roughly 20 to 50% is absorbed, although absorption is highly variable. First-pass metabolism, mode of administration, and drug interactions all affect cyclosporine absorption. Food decreases the absorption of NEORAL ® and SANGCYA ® . Cyclosporine is extremely hydrophobic. The IV formulation contains 33% alcohol and a castor oil vehicle to solubilize the drug, which is believed to account for occasionally severe hypersensitivity reactions. Oral preparations can contain corn, castor or olive oil and ethanol, but in lower concentrations.
- AUC dose normalized area under the curve
- the '382 patent describes hydrosols of cyclosporine in an intravenous applicable, stabilized, pharmaceutically acceptable form, which is suspended or dry.
- the hydrosol formulations are obtained by controlled precipitation methods. Such methods are disadvantageous in that they result in solid dose formulations having a low drug to surface stabilizer ratio, and liquid dispersion formulations having a low solid content. This is because controlled precipitation methods require an excess amount of surface stabilizer and water to produce small-sized precipitated particles. The excess of surface stabilizer produces solid dose compositions having a large quantity of surface stabilizer and a small quantity of drug. and the excess of water produces a liquid dispersion formulation having a low solids content and, therefore, a low drug content.
- a high drug content for a solid dose or liquid dispersion formulation is preferred because it produces a more concentrated dosage formulation.
- Concentrated dosage forms of cyclosporine are particularly desirable because the dosage for this drug is relatively high, i.e., about 100 mg a day or more.
- a dosage formulation having a low drug content, but requiring a high daily dosage results in either a large pill, capsule, or quantity of fluid, or multiple doses of such formulations, to be administered to the patient.
- a concentrated dosage form allows minimization of the size of the orally administered pill or capsule or number of daily administrations.
- the '822 patent is directed to aqueous suspension formulations of amorphous cyclosporin A containing lower alkanols as solubilizing agents and a polyoxyalkylene surfactant.
- amorphous cyclosporin A containing lower alkanols as solubilizing agents and a polyoxyalkylene surfactant.
- alcohol solubilizing agents are frequently undesirable because they can an trigger an allergic response in a patient.
- Such solubilizing agents are often required for prior art cyclosporine compositions to increase the solubility of the cyclosporine.
- a drug must be absorbed by a patient prior to taking effect.
- pharmaceutical formulations of highly insoluble drugs additionally contain solubilizing agents to aid in absorption of the drug following administration.
- the present invention is directed to nanoparticulate compositions of amorphous cyclosporine and, adsorbed to the surface of the cyclosporine, at least one non-crosslinked surface stabilizer.
- the cyclosporine particles of the nanoparticulate composition have an effective average particle size of less than about 2000 nm.
- the invention encompasses nanoparticulate compositions of a mixture of amorphous and crystalline cyclosporine and, adsorbed to the surface of the cyclosporine, at least one non-crosslinked surface stabilizer.
- the cyclosporine particles of the nanoparticulate composition have an effective average particle size of less than about 2000 nm.
- compositions comprising one or more nanoparticulate compositions of the invention.
- the pharmaceutical composition preferably comprises a nanoparticulate composition described above and a pharmaceutically acceptable carrier, as well as any desired excipients.
- the compositions which can be delivered in high dosage formulations, provide for improved consistency of cyclosporine absorption from patient to patient for a given dosage amount, exhibit decreased toxicity, and exhibit increased absorption as compared to conventional cyclosporine formulations.
- a first method comprises contacting amorphous cyclosporine, or a mixture of amo ⁇ hous and crystalline cyclosporine, with at least one surface stabilizer for a time and under conditions sufficient to provide a stable nanoparticulate composition.
- the surface stabilizer can be contacted with the cyclosporine particles either before, during, or after size reduction of the cyclosporine particles.
- the cyclosporine particles of the nanoparticulate composition have an effective average particle size of less than about 2000 nm.
- the present invention is further directed to methods of treatment comprising administering to a mammal in need a therapeutically effective amount of a nanoparticulate composition according to the invention.
- the nanoparticulate cyclosporine composition can be administered via any conventional route.
- FIGURES Figure 1 : Shows the results of x-ray powder diffraction of raw cyclosporine drug substance;
- Figure 2 Shows the results of x-ray powder diffraction of a milled cyclosporine formulation having Pluronic® F 108 as a surface stabilizer; and
- Figure 3 Shows the results of x-ray powder diffraction of a milled cyclosporine formulation having HPC-SL as a surface stabilizer.
- the present invention is directed to compositions comprising nanoparticulate amorphous cyclosporine, or a mixture of amorphous and crystalline cyclosporine, and methods of making and using such nanoparticulate compositions.
- singular terms are used for simplicity of expression only and are not intended to limit the invention or aspects of the invention to singular embodiments.
- a surface stabilizer is meant to describe "one or more" surface stabilizers unless explicitly indicated otherwise.
- crystalline drugs could be formulated into nanoparticulate compositions, as taught by the '684 patent.
- a surface stabilizer adsorbs to the crystalline surface of the drug and acts as a steric barrier to other drug particles to prevent agglomeration.
- amo ⁇ hous drugs could not be utilized in nanoparticulate compositions described by the '684 patent.
- Amo ⁇ hous drugs do not have an intermolecular lattice structure, which is characteristic of the crystalline solid state. Su ⁇ risingly, it was discovered that amo ⁇ hous cyclosporine can be inco ⁇ orated into a nanoparticulate composition.
- amo ⁇ hous compound has a higher energy level than a crystalline compound. Because of this, an amo ⁇ hous compound is generally unstable, as in nature the compound prefers to convert to the lower energy crystalline state. Because amo ⁇ hous compounds have a higher energy level than crystalline compounds, it is preferable that a drug be in an amo ⁇ hous state. The amo ⁇ hous state is less stable than the crystalline state; therefore, a solid will be more soluble in the amo ⁇ hous state than in the crystalline state. Improved solubility will lead to rapid and more complete dissolution, and in the case of a poorly soluble drug substance, improved bioavailabihty.
- compositions of the invention comprise nanoparticulate amo ⁇ hous cyclosporine, or a mixture of amorphous and crystalline cyclosporine. having one or more surface stabilizers adsorbed to the surface of the cyclosporine.
- Surface stabilizers useful herein physically adhere to the surface of the nanoparticulate cyclosporine but do not chemically react with the cyclosporine itself.
- Individually adsorbed molecules of the surface stabilizer are essentially free of intermolecular crosslinkages.
- the present invention also includes nanoparticulate compositions formulated into compositions together with one or more non-toxic physiologically acceptable carriers, adjuvants, or vehicles, collectively referred to as earners, for parenteral injection, for oral administration, for rectal or topical administration, or the like.
- the present invention further includes nanoparticulate compositions in solid dose formulations and liquid dispersion formulations.
- the cyclosporins comprise a class of cyclic non-polar oligopeptides having valuable immunosuppressive, anti-inflammatory, and anti-parasitic activity.
- the first of the cyclosporins to be isolated and what has been termed the "parent" compound of the class is the naturally occurring fungal metabolite referred to simply as “cyclosporine” or as “cyclosporin A.”
- cyclosporin A Since the discovery of cyclosporin A, a wide variety of naturally occuning cyclosporins have been isolated and identified and other non-naturally occurring cyclosporins have been prepared by synthetic means or via modified culture techniques. Such compounds are known in the art and are described, for example, in U.S. Patent No. 5,389,382 and in The Merck Index (12 th ed. 1996) at 464-465.
- the term cyclosporine is meant to include both cyclosporin A and other cyclosporins. such as cyclosporins B through I and synthetic analogues thereof.
- the preferred cyclosporin used herein is cyclosporin A.
- the cyclosporine compositions of the present invention are either partiall ⁇ or predominantly amorphous in nature. This is so even though the starting cyclosporine compound used to obtain the nanoparticulate compositions may be predominantly crystalline in nature.
- amorphous is a term with a recognized meaning in the chemical arts and describes a structure that is non-crystalline, i.e., a structure that lacks an intermolecular lattice structure. Whether the nanoparticulate composition is in a crystalline or amorphous state can be determined, for example, by X-ray powder diffraction patterns or other methods known to the skilled artisan.
- Suitable surface stabilizers can preferably be selected from known organic and inorganic pharmaceutical excipients. Such excipients include various polymers, low molecular weight oligomers, natural products, and surfactants. Preferred surface stabilizers include nonionic and ionic surfactants. Two or more surface stabilizers can be used in combination.
- surface stabilizers include cetyl pyridinium chloride, gelatin, casein, lecithin (phosphatides), dextran, glycerol, gum acacia, cholesterol, tragacanth, stearic acid, benzalkonium chloride, calcium stearate, glycerol monostearate, cetostearyl alcohol, cetomacrogol emulsifying wax, sorbitan esters, polyoxyethylene alkyl ethers (e.g., macrogol ethers such as cetomacrogol 1000), polyoxyethylene castor oil derivatives, polyoxyethylene sorbitan fatty acid esters (e.g., the commercially available Tweens ® such as e.g., Tween 20 ® and Tween 80 ® (ICI Specialty Chemicals)); polyethylene glycols (e.g., Carbowaxs 3350 ® and 1450 ® , and Carbopol 934* (Union Carbide)), dode
- HPC-SL, and HPC-L hydroxypropyl methylcellulose
- HPMC hydroxypropyl methylcellulose
- carboxymethylcellulose sodium methylcellulose, hydroxyethylcellulose, hydroxypropylcellulose, hydroxypropylmethyl-cellulose phthalate, noncrystalline cellulose, magnesium aluminum silicate, triethanolamine, polyvinyl alcohol (PVA), polyvinylpyrrolidone (PVP), 4-(l,l,3,3-tetramethylbutyl)- phenol polymer with ethylene oxide and formaldehyde (also known as tyloxapol), poloxamers (e.g., Pluronics F68 ® and F108 ® , which are block copolymers of ethylene oxide and propylene oxide); poloxamines (e.g..
- Tetronic 908 ® also known as Poloxamine 908 ® , which is a tetrafunctional block copolymer derived from sequential addition of propylene oxide and ethylene oxide to ethylenediamine (BASF Co ⁇ oration. Parsippany, N.J.)); a charged phospholipid such as dimyristoyl phophatidyl glycerol.
- DOSS dioctylsulfosuccinate
- Tetronic 1508 ® T- 1508
- dialkylesters of sodium sulfosuccinic acid e.g., Aerosol OT ® , which is a dioctyl ester of sodium sulfosuccinic acid (American Cyanamid)
- Duponol P ® which is a sodium lauryl sulfate (DuPont)
- Tritons X-200* which is an alkyl aryl polyether sulfonate (Rohm and Haas)
- Crodestas F-l 10 ® which is a mixture of sucrose stearate and sucrose distearate (Croda Inc.); p-isononylphenoxypoly-(glycidol), also known as Olin-IOG* or Surfactant 10-G ® (Olin Chemicals, Stamford, CT); Crodestas SL-40
- the invention includes that each of the above-described stabilizers or other stabilizers described herein or described in a reference cited herein can be used either alone, in combination with each other, or with other surface stabilizers.
- the compositions of the invention contain nanoparticles which have an effective average particle size of less than about 2000 nm, less than about 1500 nm, less than about 1000 nm, less than about 800 nm, less than about 700 nm, less than about 600 nm, less than about 500 nm, less than about 400 nm, less than about 300 nm, less than about 200 nm, less than about 100 nm, or less than about 50 nm. as measured by light-scattering methods or other methods accepted in the art.
- an effective average particle size of less than about 2000 nm it is meant that at least 50% of the drug particles have a weight average particle size of less than about 2000 nm when measured by light scattering or other conventional techniques.
- At least 70% of the drug particles have an average particle size of less than about 2000 nm, more preferably at least 90% of the drug particles have an average particle size of less than about 2000 nm, and even more preferably at least about 95% of the particles have a weight average particle size of less than about 2000 nm.
- Preferable ratios of cyclosporine to surface stabilizer are about 10: 1 to about 1.5:1, by weight. With liquid dispersions, preferred drug content is about 50% to about 2% by weight.
- the optimal effective average particle size of the invention can be obtained by controlling the process of particle size reduction, such as by controlling the milling time and the amount of surface stabilizer added. Particle growth and particle aggregation can also be minimized by milling the composition under colder temperatures and by storing the final composition at colder temperatures.
- Milling to obtain a nanoparticulate composition comprises dispersing cyclosporine particles in a liquid dispersion medium, followed by applying mechanical means in the presence of grinding media to reduce the particle size of the cyclosporine to the desired effective average particle size.
- the cyclosporine particles can be reduced in size in the presence of one or more surface stabilizers.
- the cyclosporine particles can be contacted with one or more surface stabilizers after attrition.
- Other compounds, such as a diluent can be added to the cyclosporine/surface stabilizer composition during the size reduction process.
- Dispersions can be manufactured continuously or in a batch mode.
- the resultant nanoparticulate cyclosporine dispersion can be utilized in solid or liquid dosage formulations.
- Exemplary useful mills include low energy mills, such as a roller or ball mill, and high energy mills, such as Dyno mills, Netzsch mills, DC mills, and Planetary mills.
- the starting cyclosporine composition can be predominantly crystalline, predominantly amo ⁇ hous, or a mixture thereof.
- the resultant cyclosporine composition is predominantly amo ⁇ hous.
- a solid dosage formulation can be prepared by drying the nanoparticulate amorphous cyclosporine, or mixture of amo ⁇ hous and crystalline cyclosporine, following grinding.
- a preferred drying method is spray drying. The spray drying process is used to obtain a nanoparticulate powder following the milling process used to transform the cyclosporine into nanoparticles. Such a nanoparticulate powder can be formulated into tablets for oral administration.
- nanoparticulate compositions of the invention can be administered to humans and animals either orally, rectally, parenterally (intravenous, intramuscular, or subcutaneous), intracisternally, intravaginally, intraperitoneally, locally (powders, ointments or drops), or as a buccal or nasal spray.
- compositions suitable for parenteral injection may comprise physiologically acceptable sterile aqueous or nonaqueous solutions, dispersions, suspensions or emulsions and sterile powders for reconstitution into sterile injectable solutions or dispersions.
- suitable aqueous and nonaqueous carriers, diluents, solvents, or vehicles including water, ethanol, polyols (propyleneglycol, polyethyleneglycol, glycerol, and the like), suitable mixtures thereof, vegetable oils (such as olive oil) and injectable organic esters such as ethyl oleate.
- Proper fluidity can be maintained, for example, by the use of a coating such as lecithin, by the maintenance of the required particle size in the case of dispersions and by the use of surfactants.
- the nanoparticulate compositions may also contain adjuvants such as preserving, wetting, emulsifying, and dispensing agents. Prevention of the growth of microorganisms can be ensured by various antibacterial and antifungal agents, such as parabens, chlorobutanol. phenol, sorbic acid, and the like. It may also be desirable to include isotonic agents, such as sugars, sodium chloride, and the like. Prolonged abso ⁇ tion of the injectable pharmaceutical form can be brought about by the use of agents delaying abso ⁇ tion, such as aluminum monostearate and gelatin.
- Solid dosage forms for oral administration include capsules, tablets, pills, powders, and granules.
- the active compound is admixed with at least one of the following: (a) one or more inert excipients (or carrier), such as dicalcium phosphate; (b) fillers or extenders, such as starches, lactose, sucrose, glucose, mannitol, and silicic acid; (c) binders, such as carboxymethylcellulose, alignates, gelatin, polyvinylpyrrolidone, sucrose and acacia; (d) humectants, such as glycerol; (e) disintegrating agents, such as agar-agar, calcium carbonate, potato or tapioca starch, alginic acid, certain complex silicates, and sodium carbonate; (f) solution retarders, such as paraffin; (g) absorption accelerators, such as quaternary ammonium compounds; (h) wetting agents, such as cetyl alcohol
- Liquid dosage forms for oral administration include pharmaceutically acceptable emulsions, solutions, suspensions, syrups, and elixirs.
- the liquid dosage forms may comprise inert diluents commonly used in the art, such as water or other solvents, solubilizing agents, and emulsifiers.
- Exemplary emulsifiers are ethyl alcohol, isopropyl alcohol, ethyl carbonate, ethyl acetate, benzyl alcohol, benzyl benzoate, propyleneglycol, 1,3-butyleneglycol, dimethylformamide, oils, such as cottonseed oil, groundnut oil, corn germ oil, olive oil, castor oil, and sesame oil, glycerol, tetrahydrofurfuryl alcohol, polyethyleneglycols, fatty acid esters of sorbitan, or mixtures of these substances, and the like.
- the composition can also include adjuvants, such as wetting agents, emulsifying and suspending agents, sweetening, flavoring, and perfuming agents.
- Actual dosage levels of active ingredients in the nanoparticulate compositions of the invention may be varied to obtain an amount of active ingredient that is effective to obtain a desired therapeutic response for a particular composition and method of administration.
- the selected dosage level therefore depends upon the desired therapeutic effect, on the route of administration, on the desired duration of treatment, and other factors.
- the total daily dose of the compounds of this invention administered to a host in single or divided dose can van' widely depending upon a variety of factors, including the body weight, general health, sex, diet, time and route of administration, rates of abso ⁇ tion and excretion, combination with other drugs, and the severity of the particular condition being treated.
- the recommended daily dosage for NEORAL ® ranges from 9 ⁇ 3 mg/kg/day for renal transplant patients to 2.5 mg/kg/day for psoriasis and rheumatoid arthritis, while the suggested initial oral dosage of SANDIMMUNE ® for transplant patients is 10-18 mg/kg/day.
- the purpose of this example was to prepare nanoparticulate cyclosporine formulations in which the cyclosporine is predominantly amo ⁇ hous.
- the nanoparticulate amo ⁇ hous cyclosporine formulations described in Table 1 were obtained using high energy media milling techniques. All milling experiments utilized a DYNO-MILL® Type KDL (Willy Bachofen AG. Basel,
- Cyclosporine was manufactured by the North China Pharmaceutical Co ⁇ oration (Shijiazhuang, China). Particle size distributions were determined using a Horiba LA-910 light-scattering particle size analyzer (Horiba Instruments, Irvine. CA).
- the nanoparticulate composition (2) was prepared by dissolving 1.28 g of HPC-SL (Nippon Soda) and 0.085 g of sodium lauryl sulfate (SLS) in 79.38 g of deionized water.
- the stabilizer solution, along with 4.25 g of cyclosporine drug substance and 500 ⁇ m polymeric attrition media were charged into the milling chamber.
- the formulation was processed for 4 hours.
- the concentration of SLS was then increased to 0.15%.
- the dispersion was milled for an additional 0.5 hour and then isolated from the attrition media by filtration.
- the nanoparticulate composition (3) was prepared by dissolving 0.85 g of tyloxapol (Nycomed) in 79.9 g of deionized water.
- the stabilizer solution, along with 4.25 g of cyclosporine drug substance and 500 ⁇ m polymeric attrition media were charged into the milling chamber.
- the formulation was processed for 3 hours and then isolated from the attrition media by filtration.
- the nanoparticulate composition (4) was prepared by dissolving 0.85 g of B20-5000 (Dow Chemical) in 79.9 g of deionized water.
- the stabilizer solution, along with 4.25 g of cyclosporine drug substance and 500 ⁇ m polymeric attrition media were charged into the milling chamber.
- the formulation was processed for 4.5 hours. At that time, an additional 0.85 g of B20-5000 was added.
- the dispersion was milled for an additional 2.25 hours and then isolated from the attrition media by filtration.
- the drug substance starting material used in these examples was primarily crystalline as determined by x-ray powder diffraction, the results of which are shown in Fig. 1.
- the milled colloidal dispersions were also analyzed by x-ray powder diffraction. Upon completion of milling, a portion of each dispersion was centrifuged and the supernatant liquid decanted. The solids were washed with water and re-centrifuged several times, then dried. X-ray powder diffraction of the milled material showed the absence of sha ⁇ abso ⁇ tion lines, indicating that the material was amorphous, as shown in Figs. 2 and 3.
- Fig. 2 shows the results of x-ray powder diffraction of milled cyclosporine having Pluronic ® F 108 as a surface stabilizer
- Fig. 3 shows the results of x-ray powder diffraction of milled cyclosporine having HPC-SL as a surface stabilizer.
- the colloidal dispersions could also be prepared from amo ⁇ hous drug substance starting material.
- nanoparticulate amo ⁇ hous cyclosporine formulation can be made using a variety of surface stabilizers, using various stabilizer concentrations, and using various cyclosporine concentrations, from crystalline cyclosporine starting material.
- the pu ⁇ ose of this example was to compare the pharmacokinetic profiles between a nanoparticulate cyclosporine formulation according to the invention and a conventional cyclosporine formulation, NEORAL ® .
- the cyclosporine present in NEORAL ® is solubilized in alcohol and several additional excipients.
- a comparative study was performed between a nanoparticulate amo ⁇ hous cyclosporin A composition and NEORAL ® .
- the nanoparticulate composition consisted of 10% w/w cyclosporine, 6% w/w Pluronic® F108, and 0.1% w/w sodium lauryl sulfate (SLS).
- the composition was prepared by dissolving 90 g of Pluronic® F108 and 1.5 g of SLS in 1258.5 g of sterile water for injection, USP and then adding 150 g of cyclosporine to form a premix.
- a DYNO-MILL® Type KDL was assembled with a 600 cc recirculation chamber which was charged with 500 ⁇ m polymeric attrition media.
- the slurry was processed for 12.5 hours and then filtered through a 20 ⁇ m capsule filter to yield a nanoparticulate colloidal dispersion of cyclosporine with a mean particle size of 165 nm and 90% less than 229 nm.
- the particle size distribution was determined on a Horiba LA-910 particle size analyzer.
- Tables 2 and 3 show a summary of the Area Under the Curve (AUC) for a single 100 mg dosage of the nanoparticulate amo ⁇ hous cyclosporin A composition and NEORAL ® , respectively, administered to two groups of three dogs (GROUPS 1 and 2) over a 24 hour period.
- a greater AUC corresponds to greater bioavailabihty.
- AUC measurements for the nanoparticulate amo ⁇ hous cyclosporin A composition and NEORAL ® were measured following administration to the same animals eight days apart.
- the AUC values for the nanoparticulate amo ⁇ hous cyclosporin A composition were measured at periodic increments throughout Day 1 for the GROUP 1 dogs and at periodic increments throughout Day 8 for the GROUP 2 dogs, as shown in Table 2.
- the AUC values for NEORAL ® administration were measured at periodic increments throughout Day 1 for the GROUP 2 dogs and at periodic increments throughout Day 8 for the GROUP 1 dogs, as shown in Table 3.
- GROUP 1 (Nanoparticulate GROUP 2 (Nanoparticulate
- GROUP 2 (NEORAL ® GROUP 1 (NEORAL ®
- the AUC values for the GROUP 2 dogs for NEORAL ® administration were 6457.2, 8982.8, and 12600.6 ng/mL/hr.
- a wide variation in abso ⁇ tion is highly undesirable because it makes dosage formulation difficult and because it can result in requiring constant monitoring of the patient to ensure proper blood levels of the drug.
- the relative standard deviation (RSD) of the AUC values for each dosage form is a quantitative measure of intersubject abso ⁇ tion variability.
- the RSD of the AUC values was 25.4%
- the RSD of the AUC values when NEORAL ® was adminstered was 45.4%.
- the intersubject variability was ca 1 8 times greater for the NEORAL ® dosage form than it was for the nanoparticulate formulation
- NEORAL ® has an intersubject abso ⁇ tion variability in AUC that spans
- nanoparticulate AUC variability (lowest to highest) is only
Abstract
Description
Claims
Priority Applications (5)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
JP2001521335A JP2003508492A (en) | 1999-09-09 | 2000-09-07 | Nanoparticulate compositions comprising amorphous cyclosporin and methods of making and using such compositions |
AU71195/00A AU7119500A (en) | 1999-09-09 | 2000-09-07 | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
CA2384670A CA2384670C (en) | 1999-09-09 | 2000-09-07 | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
EP00959965A EP1210104B1 (en) | 1999-09-09 | 2000-09-07 | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
DE60027171T DE60027171T2 (en) | 1999-09-09 | 2000-09-07 | NANOPARTICLE COMPOSITIONS CONTAINING AMORPHOSIC CYCLOSPORIN AND ITS PRODUCTION PROCESS AND METHOD OF USE |
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US09/392,557 US6656504B1 (en) | 1999-09-09 | 1999-09-09 | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
US09/392,557 | 1999-09-09 |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2001017546A1 true WO2001017546A1 (en) | 2001-03-15 |
Family
ID=23551058
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/US2000/024505 WO2001017546A1 (en) | 1999-09-09 | 2000-09-07 | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions |
Country Status (8)
Country | Link |
---|---|
US (1) | US6656504B1 (en) |
EP (1) | EP1210104B1 (en) |
JP (2) | JP2003508492A (en) |
AT (1) | ATE322281T1 (en) |
AU (1) | AU7119500A (en) |
CA (1) | CA2384670C (en) |
DE (1) | DE60027171T2 (en) |
WO (1) | WO2001017546A1 (en) |
Cited By (29)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
WO2001026635A2 (en) * | 1999-10-08 | 2001-04-19 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
WO2003034822A2 (en) * | 2001-10-18 | 2003-05-01 | Bayer Cropscience Aktiengesellschaft | Powdery active ingredient formulations |
WO2003080024A2 (en) * | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of map kinase inhibitors |
US6835396B2 (en) | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
JP2005530712A (en) * | 2002-03-20 | 2005-10-13 | エラン ファーマ インターナショナル,リミティド | Nanoparticle composition of angiogenesis inhibitor |
JP2005536512A (en) * | 2002-07-16 | 2005-12-02 | エラン ファーマ インターナショナル,リミティド | Stable nanoparticulate active substance liquid dosage composition |
EP1613276A1 (en) * | 2002-12-03 | 2006-01-11 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
JP2006502859A (en) * | 2002-10-18 | 2006-01-26 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Method for producing a powdered active substance formulation using a compressible fluid |
EP1868582A1 (en) * | 2005-04-12 | 2007-12-26 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
WO2008002485A2 (en) * | 2006-06-23 | 2008-01-03 | Alza Corporation | Increased amorphous stability of poorly water soluble drugs by nanosizing |
WO2008054508A2 (en) * | 2006-04-13 | 2008-05-08 | Alza Corporation | Stable nanosized amorphous drug |
WO2009049820A2 (en) * | 2007-10-11 | 2009-04-23 | Bayer Schering Pharma Aktiengesellschaft | Amorphous formulation |
WO2009078802A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
WO2010146606A1 (en) * | 2009-06-19 | 2010-12-23 | Sun Pharma Advanced Research Company Ltd., | Nanodispersion of a drug and process for its preparation |
US7998507B2 (en) | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US8124057B2 (en) | 1998-11-12 | 2012-02-28 | Alkermes Pharma Ireland Limited | Propellant-based nanoparticulate dry powder aerosols and method of making |
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US8309136B2 (en) | 2000-09-21 | 2012-11-13 | Alkermes Pharma Ireland Limited | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions |
US8323641B2 (en) | 2002-02-04 | 2012-12-04 | Alkermes Pharma Ireland Limited | Nanoparticulate compositions having lysozyme as a surface stabilizer |
US8324274B2 (en) | 2007-12-19 | 2012-12-04 | Ardenia Invesments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
US8722091B2 (en) | 2001-09-26 | 2014-05-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US8765173B2 (en) | 2007-12-19 | 2014-07-01 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
WO2015071837A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
US9040088B2 (en) | 2002-04-12 | 2015-05-26 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
WO2017025588A1 (en) * | 2015-08-11 | 2017-02-16 | Eyesiu Medicines B.V. | Pegylated lipid nanoparticle with bioactive lipophilic compound |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
CN108553448A (en) * | 2018-05-30 | 2018-09-21 | 江西师范大学 | A kind of preparation method of the medicament slow release cellulose nano particle of pH responses |
Families Citing this family (49)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20080102121A1 (en) * | 1998-11-02 | 2008-05-01 | Elan Pharma International Limited | Compositions comprising nanoparticulate meloxicam and controlled release hydrocodone |
US20050227911A1 (en) * | 2001-09-28 | 2005-10-13 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of macromolecules |
US6878693B2 (en) * | 2001-09-28 | 2005-04-12 | Solubest Ltd. | Hydrophilic complexes of lipophilic materials and an apparatus and method for their production |
US20050191359A1 (en) * | 2001-09-28 | 2005-09-01 | Solubest Ltd. | Water soluble nanoparticles and method for their production |
US20050233003A1 (en) * | 2001-09-28 | 2005-10-20 | Solubest Ltd. | Hydrophilic dispersions of nanoparticles of inclusion complexes of salicylic acid |
DE10154464B4 (en) * | 2001-11-08 | 2005-10-20 | Max Delbrueck Centrum | Orally administrable pharmaceutical preparation comprising liposomally encapsulated taxol |
US7700851B2 (en) * | 2001-11-13 | 2010-04-20 | U.S. Smokeless Tobacco Company | Tobacco nicotine demethylase genomic clone and uses thereof |
EP1587499A1 (en) * | 2003-01-31 | 2005-10-26 | Elan Pharma International Limited | Nanoparticulate topiramate formulations |
US20040208833A1 (en) * | 2003-02-04 | 2004-10-21 | Elan Pharma International Ltd. | Novel fluticasone formulations |
US8512727B2 (en) | 2003-03-03 | 2013-08-20 | Alkermes Pharma Ireland Limited | Nanoparticulate meloxicam formulations |
US20100297252A1 (en) | 2003-03-03 | 2010-11-25 | Elan Pharma International Ltd. | Nanoparticulate meloxicam formulations |
CA2534924A1 (en) * | 2003-08-08 | 2005-02-24 | Elan Pharma International Ltd. | Novel metaxalone compositions |
US7879360B2 (en) * | 2003-11-05 | 2011-02-01 | Elan Pharma International, Ltd. | Nanoparticulate compositions having a peptide as a surface stabilizer |
EP2623095A1 (en) * | 2004-11-16 | 2013-08-07 | Elan Pharma International Limited | Injectable nanoparticulate olanzapine formulations |
UA89513C2 (en) * | 2004-12-03 | 2010-02-10 | Элан Фарма Интернешнл Лтд. | Nanoparticulate raloxifene hydrochloride composition |
CA2590675A1 (en) * | 2004-12-15 | 2006-06-22 | Elan Pharma International Ltd. | Nanoparticulate tacrolimus formulations |
WO2006069098A1 (en) * | 2004-12-22 | 2006-06-29 | Elan Pharma International Ltd. | Nanoparticulate bicalutamide formulations |
WO2006074218A2 (en) * | 2005-01-06 | 2006-07-13 | Elan Pharma International Ltd. | Nanoparticulate candesartan formulations |
US20060204588A1 (en) * | 2005-03-10 | 2006-09-14 | Elan Pharma International Limited | Formulations of a nanoparticulate finasteride, dutasteride or tamsulosin hydrochloride, and mixtures thereof |
JP2008533174A (en) * | 2005-03-16 | 2008-08-21 | エラン ファーマ インターナショナル リミテッド | Nanoparticulate leukotriene receptor antagonist / corticosteroid preparation |
NZ561666A (en) | 2005-03-17 | 2010-05-28 | Elan Pharma Int Ltd | Nanoparticulate biphosphonate compositions |
BRPI0609700A2 (en) * | 2005-03-23 | 2010-04-20 | Elan Pharma Int Ltd | nanoparticulate corticosteroid and antihistamine formulations |
MX2007012778A (en) * | 2005-04-12 | 2008-01-11 | Elan Pharma Int Ltd | Nanoparticulate quinazoline derivative formulations. |
US20060246141A1 (en) * | 2005-04-12 | 2006-11-02 | Elan Pharma International, Limited | Nanoparticulate lipase inhibitor formulations |
DE112006001606T5 (en) | 2005-06-08 | 2009-07-09 | Elan Pharma International Ltd., Athlone | Nanoparticulate and controlled release composition comprising cefditoren |
US7276476B2 (en) | 2005-07-13 | 2007-10-02 | Allergan, Inc. | Cyclosporin compositions |
US7297679B2 (en) | 2005-07-13 | 2007-11-20 | Allergan, Inc. | Cyclosporin compositions |
US20070015691A1 (en) | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7202209B2 (en) | 2005-07-13 | 2007-04-10 | Allergan, Inc. | Cyclosporin compositions |
US20070015693A1 (en) * | 2005-07-13 | 2007-01-18 | Allergan, Inc. | Cyclosporin compositions |
US7288520B2 (en) | 2005-07-13 | 2007-10-30 | Allergan, Inc. | Cyclosporin compositions |
US7501393B2 (en) | 2005-07-27 | 2009-03-10 | Allergan, Inc. | Pharmaceutical compositions comprising cyclosporins |
EP2279727A3 (en) | 2005-09-15 | 2011-10-05 | Elan Pharma International Limited | Nanoparticulate aripiprazole formulations |
US7745400B2 (en) * | 2005-10-14 | 2010-06-29 | Gregg Feinerman | Prevention and treatment of ocular side effects with a cyclosporin |
US9839667B2 (en) | 2005-10-14 | 2017-12-12 | Allergan, Inc. | Prevention and treatment of ocular side effects with a cyclosporin |
US8367112B2 (en) * | 2006-02-28 | 2013-02-05 | Alkermes Pharma Ireland Limited | Nanoparticulate carverdilol formulations |
TWI434926B (en) * | 2006-12-11 | 2014-04-21 | Alcon Res Ltd | Use of peo-pbo block copolymers in ophthalmic compositions |
US8703204B2 (en) | 2007-05-03 | 2014-04-22 | Bend Research, Inc. | Nanoparticles comprising a cholesteryl ester transfer protein inhibitor and anon-ionizable polymer |
US8309129B2 (en) | 2007-05-03 | 2012-11-13 | Bend Research, Inc. | Nanoparticles comprising a drug, ethylcellulose, and a bile salt |
US9545384B2 (en) | 2007-06-04 | 2017-01-17 | Bend Research, Inc. | Nanoparticles comprising drug, a non-ionizable cellulosic polymer and tocopheryl polyethylene glocol succinate |
WO2008149192A2 (en) | 2007-06-04 | 2008-12-11 | Pfizer Products Inc. | Nanoparticles comprising a non-ionizable cellulosic polymer and an amphiphilic non-ionizable block copolymer |
US9724362B2 (en) | 2007-12-06 | 2017-08-08 | Bend Research, Inc. | Pharmaceutical compositions comprising nanoparticles and a resuspending material |
US9233078B2 (en) | 2007-12-06 | 2016-01-12 | Bend Research, Inc. | Nanoparticles comprising a non-ionizable polymer and an Amine-functionalized methacrylate copolymer |
WO2009117410A2 (en) * | 2008-03-17 | 2009-09-24 | Board Of Regents, The University Of Texas System | Formation of nanostructured particles of poorly water soluble drugs and recovery by mechanical techniques |
JP6072539B2 (en) | 2009-05-27 | 2017-02-01 | アルカーメス ファーマ アイルランド リミテッド | Reduction of flaky aggregation in nanoparticulate active agent compositions |
US20120128740A1 (en) | 2009-06-19 | 2012-05-24 | Filipcsei Genoveva | Nanostructured sildenafil base, its pharmaceutically acceptable salts and co-crystals, compositions of them, process for the preparation thereof and pharmaceutical compositions containing them |
TWI547522B (en) * | 2009-07-07 | 2016-09-01 | 愛爾康研究有限公司 | Ethyleneoxide butyleneoxide block copolymer compositions |
WO2011153349A1 (en) | 2010-06-02 | 2011-12-08 | Alcon Research, Ltd. | Ophthalmic compositions comprising pbo-peo-pbo block copolymers |
MX362271B (en) * | 2011-05-27 | 2019-01-10 | Allergan Inc | A crystalline form of cyclosporine a, methods of preparation, and methods for use thereof. |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2608427A1 (en) * | 1986-12-19 | 1988-06-24 | Sandoz Sa | HYDROSOLS OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO1996014079A1 (en) * | 1994-11-03 | 1996-05-17 | Arzneimittelwerk Dresden Gmbh | Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them |
WO1996031202A1 (en) * | 1995-04-03 | 1996-10-10 | Elan Corporation, Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
WO1997035603A1 (en) * | 1996-03-25 | 1997-10-02 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
Family Cites Families (32)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US3911099A (en) * | 1974-01-23 | 1975-10-07 | Defoney Brenman Mayes & Baron | Long-acting articles for oral delivery and process |
DE3013839A1 (en) | 1979-04-13 | 1980-10-30 | Freunt Ind Co Ltd | METHOD FOR PRODUCING AN ACTIVATED PHARMACEUTICAL COMPOSITION |
US4826689A (en) | 1984-05-21 | 1989-05-02 | University Of Rochester | Method for making uniformly sized particles from water-insoluble organic compounds |
US4663364A (en) | 1984-09-05 | 1987-05-05 | Kao Corporation | Biocidal fine powder, its manufacturing method and a suspension for agricultural use containing the above powder |
US4783484A (en) | 1984-10-05 | 1988-11-08 | University Of Rochester | Particulate composition and use thereof as antimicrobial agent |
US4727077A (en) | 1985-02-20 | 1988-02-23 | Ishihara Sangyo Kaisha Ltd. | Benzoyl urea compounds, process for their production, and antitumorous compositions containing them |
JPS62185013A (en) | 1986-02-08 | 1987-08-13 | Green Cross Corp:The | Easily absorbable pharmaceutical composition |
EP0262560A3 (en) | 1986-09-29 | 1989-07-05 | Ishihara Sangyo Kaisha, Ltd. | Benzoyl urea compound |
US4983605A (en) | 1986-10-23 | 1991-01-08 | Ishihara Sangyo Kaisha Ltd. | Pharmaceutical composition |
JP2661709B2 (en) | 1988-07-08 | 1997-10-08 | ダウ・ケミカル日本株式会社 | Production method of highly active pesticide wettable powder |
JPH02196719A (en) | 1989-01-24 | 1990-08-03 | Green Cross Corp:The | Powdery drug composition |
US5145684A (en) | 1991-01-25 | 1992-09-08 | Sterling Drug Inc. | Surface modified drug nanoparticles |
US5399363A (en) | 1991-01-25 | 1995-03-21 | Eastman Kodak Company | Surface modified anticancer nanoparticles |
MX9201782A (en) * | 1991-04-19 | 1992-10-01 | Sandoz Ag | PARTICLES OF BIOLOGICALLY ACTIVE SUBSTANCES, SUBSTANTIALLY INSOLUBLE IN WATER, PROCESS FOR THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITION THAT CONTAINS THEM. |
EP0593627A1 (en) | 1991-07-05 | 1994-04-27 | The University Of Rochester | Ultrasmall non-aggregated porous particles entrapping gas-bubbles |
AU660852B2 (en) | 1992-11-25 | 1995-07-06 | Elan Pharma International Limited | Method of grinding pharmaceutical substances |
US5429824A (en) | 1992-12-15 | 1995-07-04 | Eastman Kodak Company | Use of tyloxapole as a nanoparticle stabilizer and dispersant |
US5439686A (en) | 1993-02-22 | 1995-08-08 | Vivorx Pharmaceuticals, Inc. | Methods for in vivo delivery of substantially water insoluble pharmacologically active agents and compositions useful therefor |
US5916596A (en) | 1993-02-22 | 1999-06-29 | Vivorx Pharmaceuticals, Inc. | Protein stabilized pharmacologically active agents, methods for the preparation thereof and methods for the use thereof |
US5718388A (en) | 1994-05-25 | 1998-02-17 | Eastman Kodak | Continuous method of grinding pharmaceutical substances |
TW384224B (en) | 1994-05-25 | 2000-03-11 | Nano Sys Llc | Method of preparing submicron particles of a therapeutic or diagnostic agent |
US5587143A (en) | 1994-06-28 | 1996-12-24 | Nanosystems L.L.C. | Butylene oxide-ethylene oxide block copolymer surfactants as stabilizer coatings for nanoparticle compositions |
US5622938A (en) | 1995-02-09 | 1997-04-22 | Nano Systems L.L.C. | Sugar base surfactant for nanocrystals |
US5510118A (en) * | 1995-02-14 | 1996-04-23 | Nanosystems Llc | Process for preparing therapeutic compositions containing nanoparticles |
US5565188A (en) | 1995-02-24 | 1996-10-15 | Nanosystems L.L.C. | Polyalkylene block copolymers as surface modifiers for nanoparticles |
US5834017A (en) * | 1995-08-25 | 1998-11-10 | Sangstat Medical Corporation | Oral cyclopsporin formulations |
US5766629A (en) * | 1995-08-25 | 1998-06-16 | Sangstat Medical Corporation | Oral cyclosporin formulations |
BR9606603A (en) * | 1995-08-25 | 1997-09-30 | Sangstat Medical Corp | Formulation of cyclosporine aqueous dispersion of cyclosporine kit nanoparticles and process of preparation of aqueous dispersion of cyclosporine particles |
JP2000516244A (en) | 1996-08-22 | 2000-12-05 | リサーチ・トライアングル・ファーマシューティカルズ | Composition containing fine particles of water-insoluble substance and method for producing the same |
IT1298575B1 (en) * | 1998-02-06 | 2000-01-12 | Vectorpharma Int | PHARMACEUTICAL COMPOSITIONS IN THE FORM OF NANOPARTICLES INCLUDING LIPID SUBSTANCES AND ANTIPHILIC SUBSTANCES AND RELATED PROCESS OF |
EP1079808B1 (en) * | 1998-05-29 | 2004-02-11 | Skyepharma Canada Inc. | Thermoprotected microparticle compositions and process for terminal steam sterilization thereof |
DE19932157A1 (en) * | 1999-07-13 | 2001-01-18 | Pharmasol Gmbh | Process for the gentle production of ultra-fine microparticles and nanoparticles |
-
1999
- 1999-09-09 US US09/392,557 patent/US6656504B1/en not_active Expired - Fee Related
-
2000
- 2000-09-07 CA CA2384670A patent/CA2384670C/en not_active Expired - Fee Related
- 2000-09-07 AT AT00959965T patent/ATE322281T1/en not_active IP Right Cessation
- 2000-09-07 EP EP00959965A patent/EP1210104B1/en not_active Expired - Lifetime
- 2000-09-07 JP JP2001521335A patent/JP2003508492A/en active Pending
- 2000-09-07 AU AU71195/00A patent/AU7119500A/en not_active Abandoned
- 2000-09-07 WO PCT/US2000/024505 patent/WO2001017546A1/en active IP Right Grant
- 2000-09-07 DE DE60027171T patent/DE60027171T2/en not_active Expired - Lifetime
-
2010
- 2010-08-24 JP JP2010186933A patent/JP2011006450A/en active Pending
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
FR2608427A1 (en) * | 1986-12-19 | 1988-06-24 | Sandoz Sa | HYDROSOLS OF PHARMACOLOGICALLY ACTIVE SUBSTANCES AND PHARMACEUTICAL COMPOSITIONS CONTAINING THEM |
WO1996014079A1 (en) * | 1994-11-03 | 1996-05-17 | Arzneimittelwerk Dresden Gmbh | Novel cyclosporine preparation forms for oral administration of simple composition and high bio-availability, and process for producing them |
WO1996031202A1 (en) * | 1995-04-03 | 1996-10-10 | Elan Corporation, Plc | Controlled release biodegradable micro- and nanospheres containing cyclosporin |
WO1997035603A1 (en) * | 1996-03-25 | 1997-10-02 | Sangstat Medical Corporation | Cyclosporin a formulations as nanoparticles |
Cited By (55)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US8236352B2 (en) | 1998-10-01 | 2012-08-07 | Alkermes Pharma Ireland Limited | Glipizide compositions |
US8293277B2 (en) | 1998-10-01 | 2012-10-23 | Alkermes Pharma Ireland Limited | Controlled-release nanoparticulate compositions |
US8124057B2 (en) | 1998-11-12 | 2012-02-28 | Alkermes Pharma Ireland Limited | Propellant-based nanoparticulate dry powder aerosols and method of making |
US7288267B2 (en) | 1999-10-08 | 2007-10-30 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
WO2001026635A3 (en) * | 1999-10-08 | 2001-09-13 | Elan Pharma Int Ltd | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US6428814B1 (en) | 1999-10-08 | 2002-08-06 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
WO2001026635A2 (en) * | 1999-10-08 | 2001-04-19 | Elan Pharma International Ltd. | Bioadhesive nanoparticulate compositions having cationic surface stabilizers |
US7998507B2 (en) | 2000-09-21 | 2011-08-16 | Elan Pharma International Ltd. | Nanoparticulate compositions of mitogen-activated protein (MAP) kinase inhibitors |
US8309136B2 (en) | 2000-09-21 | 2012-11-13 | Alkermes Pharma Ireland Limited | In vitro methods for evaluating the in vivo effectiveness of dosage forms of microparticulate or nanoparticulate active agent compositions |
US8067032B2 (en) | 2000-12-22 | 2011-11-29 | Baxter International Inc. | Method for preparing submicron particles of antineoplastic agents |
US9700866B2 (en) | 2000-12-22 | 2017-07-11 | Baxter International Inc. | Surfactant systems for delivery of organic compounds |
US6835396B2 (en) | 2001-09-26 | 2004-12-28 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
US8722091B2 (en) | 2001-09-26 | 2014-05-13 | Baxter International Inc. | Preparation of submicron sized nanoparticles via dispersion lyophilization |
WO2003034822A3 (en) * | 2001-10-18 | 2007-12-06 | Bayer Cropscience Ag | Powdery active ingredient formulations |
WO2003034822A2 (en) * | 2001-10-18 | 2003-05-01 | Bayer Cropscience Aktiengesellschaft | Powdery active ingredient formulations |
US8652464B2 (en) | 2002-02-04 | 2014-02-18 | Alkermes Pharma Ireland Limited | Method of treatment using nanoparticulate compositions having lysozyme as a surface stabilizer |
US8323641B2 (en) | 2002-02-04 | 2012-12-04 | Alkermes Pharma Ireland Limited | Nanoparticulate compositions having lysozyme as a surface stabilizer |
JP2005526785A (en) * | 2002-03-20 | 2005-09-08 | エラン ファーマ インターナショナル,リミティド | Nanoparticle composition of MAP kinase inhibitor |
JP2005530712A (en) * | 2002-03-20 | 2005-10-13 | エラン ファーマ インターナショナル,リミティド | Nanoparticle composition of angiogenesis inhibitor |
WO2003080024A3 (en) * | 2002-03-20 | 2004-04-08 | Elan Pharma Int Ltd | Nanoparticulate compositions of map kinase inhibitors |
JP4842514B2 (en) * | 2002-03-20 | 2011-12-21 | エラン ファーマ インターナショナル,リミティド | Nanoparticle composition of angiogenesis inhibitor |
WO2003080024A2 (en) * | 2002-03-20 | 2003-10-02 | Elan Pharma International, Ltd. | Nanoparticulate compositions of map kinase inhibitors |
US9040088B2 (en) | 2002-04-12 | 2015-05-26 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US9107827B2 (en) | 2002-04-12 | 2015-08-18 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US9101549B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
US9101540B2 (en) | 2002-04-12 | 2015-08-11 | Alkermes Pharma Ireland Limited | Nanoparticulate megestrol formulations |
JP4776229B2 (en) * | 2002-07-16 | 2011-09-21 | エラン ファーマ インターナショナル,リミティド | Stable nanoparticulate active substance liquid dosage composition |
JP2005536512A (en) * | 2002-07-16 | 2005-12-02 | エラン ファーマ インターナショナル,リミティド | Stable nanoparticulate active substance liquid dosage composition |
JP2006502859A (en) * | 2002-10-18 | 2006-01-26 | バイエル・テクノロジー・サービシーズ・ゲゼルシャフト・ミット・ベシュレンクテル・ハフツング | Method for producing a powdered active substance formulation using a compressible fluid |
EP2263651A3 (en) * | 2002-12-03 | 2011-09-14 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
EP1613276A1 (en) * | 2002-12-03 | 2006-01-11 | Elan Pharma International Limited | Low viscosity liquid dosage forms |
EP1868582A4 (en) * | 2005-04-12 | 2011-06-22 | Elan Pharma Int Ltd | Nanoparticulate and controlled release compositions comprising cyclosporine |
EP1868582A1 (en) * | 2005-04-12 | 2007-12-26 | Elan Pharma International Limited | Nanoparticulate and controlled release compositions comprising cyclosporine |
WO2008054508A3 (en) * | 2006-04-13 | 2008-11-06 | Alza Corp | Stable nanosized amorphous drug |
WO2008054508A2 (en) * | 2006-04-13 | 2008-05-08 | Alza Corporation | Stable nanosized amorphous drug |
WO2008002485A2 (en) * | 2006-06-23 | 2008-01-03 | Alza Corporation | Increased amorphous stability of poorly water soluble drugs by nanosizing |
WO2008002485A3 (en) * | 2006-06-23 | 2008-05-02 | Alza Corp | Increased amorphous stability of poorly water soluble drugs by nanosizing |
WO2009049820A3 (en) * | 2007-10-11 | 2009-06-11 | Bayer Schering Pharma Ag | Amorphous formulation |
WO2009049820A2 (en) * | 2007-10-11 | 2009-04-23 | Bayer Schering Pharma Aktiengesellschaft | Amorphous formulation |
US9993438B2 (en) | 2007-12-19 | 2018-06-12 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
USRE49742E1 (en) | 2007-12-19 | 2023-12-05 | Vivesto Ab | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
US8765173B2 (en) | 2007-12-19 | 2014-07-01 | Ardenia Investments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
US8324274B2 (en) | 2007-12-19 | 2012-12-04 | Ardenia Invesments, Ltd. | Drug delivery system for administration of a water soluble, cationic and amphiphilic pharmaceutically active substance |
US8999382B2 (en) | 2007-12-19 | 2015-04-07 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
WO2009078802A1 (en) * | 2007-12-19 | 2009-06-25 | Ardenia Investments, Ltd. | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
USRE49741E1 (en) | 2007-12-19 | 2023-12-05 | Vivesto Ab | Drug delivery system for administration of poorly water soluble pharmaceutically active substances |
US8778364B2 (en) | 2009-06-19 | 2014-07-15 | Sun Pharma Advanced Research Company Ltd. | Nanodispersion of a drug and process for its preparation |
CN102802624A (en) * | 2009-06-19 | 2012-11-28 | 太阳医药高级研发有限公司 | Nanodispersion Of A Drug And Process For Its Preparation |
WO2010146606A1 (en) * | 2009-06-19 | 2010-12-23 | Sun Pharma Advanced Research Company Ltd., | Nanodispersion of a drug and process for its preparation |
WO2015071837A1 (en) | 2013-11-12 | 2015-05-21 | Druggability Technologies Holdings Limited | Complexes of cyclosporine a and its derivatives, process for the preparation thereof and pharmaceutical compositions containing them |
WO2017025588A1 (en) * | 2015-08-11 | 2017-02-16 | Eyesiu Medicines B.V. | Pegylated lipid nanoparticle with bioactive lipophilic compound |
US10525012B2 (en) | 2015-08-11 | 2020-01-07 | Eyesiu Medicines B.V. | Pegylated lipid nanoparticle with bioactive lipophilic compound |
US10945966B2 (en) | 2015-08-11 | 2021-03-16 | Eyesiu Medicines B.V. | PEGylated lipid nanoparticle with bioactive lipophilic compound |
CN108348468A (en) * | 2015-08-11 | 2018-07-31 | Eyesiu医疗股份有限公司 | Pegylated lipids nanoparticle with bioactive lipophilic compounds |
CN108553448A (en) * | 2018-05-30 | 2018-09-21 | 江西师范大学 | A kind of preparation method of the medicament slow release cellulose nano particle of pH responses |
Also Published As
Publication number | Publication date |
---|---|
EP1210104B1 (en) | 2006-04-05 |
EP1210104A1 (en) | 2002-06-05 |
DE60027171T2 (en) | 2007-01-04 |
JP2011006450A (en) | 2011-01-13 |
CA2384670A1 (en) | 2001-03-15 |
ATE322281T1 (en) | 2006-04-15 |
AU7119500A (en) | 2001-04-10 |
DE60027171D1 (en) | 2006-05-18 |
US6656504B1 (en) | 2003-12-02 |
JP2003508492A (en) | 2003-03-04 |
CA2384670C (en) | 2011-01-04 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
CA2384670C (en) | Nanoparticulate compositions comprising amorphous cyclosporine and methods of making and using such compositions | |
CA2367096C (en) | Methods for preventing crystal growth and particle aggregation in nanoparticulate compositions | |
US20120087984A1 (en) | Stabilization of chemical compounds using nanoparticulate formulations | |
US7244451B2 (en) | Methods of making nanoparticulate drug compositions comprising copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers | |
US7825087B2 (en) | Nanoparticulate and controlled release compositions comprising cyclosporine | |
EP1585502B1 (en) | Fast-disintegrating solid dosage forms being not friable and comprising pullulan | |
EP1318788B1 (en) | Solid dose nanoparticulate compositions | |
EP1478342B1 (en) | Sterile filtered nanoparticule formulations of budesonide having tyloxapol as a surface stabilizer | |
JP4380925B2 (en) | Use of PEG-derivatized lipids as surface stabilizers for nanoparticle compositions | |
US6228399B1 (en) | Composition and method of preparing microparticles of water-insoluble substances | |
US20090238867A1 (en) | Nanoparticulate Anidulafungin Compositions and Methods for Making the Same | |
EP0812187A1 (en) | Redispersible nanoparticulate film matrices with protective overcoats | |
JP2008533165A (en) | Injectable composition of nanoparticulate immunosuppressive compounds | |
WO2009067557A1 (en) | Deferasirox pharmaceutical compositions | |
CA2428785C (en) | Nanoparticulate compositions comprising a drug and copolymers of vinyl pyrrolidone and vinyl acetate as surface stabilizers |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
AK | Designated states |
Kind code of ref document: A1 Designated state(s): AE AG AL AM AT AU AZ BA BB BG BR BY BZ CA CH CN CR CU CZ DE DK DM DZ EE ES FI GB GD GE GH GM HR HU ID IL IN IS JP KE KG KP KR KZ LC LK LR LS LT LU LV MA MD MG MK MN MW MX MZ NO NZ PL PT RO RU SD SE SG SI SK SL TJ TM TR TT TZ UA UG US UZ VN YU ZA ZW |
|
AL | Designated countries for regional patents |
Kind code of ref document: A1 Designated state(s): GH GM KE LS MW MZ SD SL SZ TZ UG ZW AM AZ BY KG KZ MD RU TJ TM AT BE CH CY DE DK ES FI FR GB GR IE IT LU MC NL PT SE BF BJ CF CG CI CM GA GN GW ML MR NE SN TD TG |
|
121 | Ep: the epo has been informed by wipo that ep was designated in this application | ||
DFPE | Request for preliminary examination filed prior to expiration of 19th month from priority date (pct application filed before 20040101) | ||
WWE | Wipo information: entry into national phase |
Ref document number: 2384670 Country of ref document: CA |
|
ENP | Entry into the national phase |
Ref country code: JP Ref document number: 2001 521335 Kind code of ref document: A Format of ref document f/p: F |
|
WWE | Wipo information: entry into national phase |
Ref document number: 2000959965 Country of ref document: EP |
|
WWP | Wipo information: published in national office |
Ref document number: 2000959965 Country of ref document: EP |
|
REG | Reference to national code |
Ref country code: DE Ref legal event code: 8642 |
|
WWG | Wipo information: grant in national office |
Ref document number: 2000959965 Country of ref document: EP |